Traditional X-rays, move over—there may be a new gold standard for joint imaging to assess even the smallest changes that can signal the onset of arthritis, as reported recently in the journal Scientific Reports.1 Utilizing the combined expertise of radiologists, rheumatologists and engineers, University of Cambridge researchers developed an algorithm to monitor the joints of…
The ACR advocates on behalf of the rheumatology community throughout the year, but it’s always especially exciting when patients join our efforts in Washington, D.C. Close to 100 patients, rheumatologists and representatives of the broader interprofessional team traveled to our nation’s capital this week to participate in the ACR’s annual Advocates for Arthritis event. Participants…
Down syndrome (trisomy 21) is one of the most common chromosomal abnormalities. According to the Genomic Resource Centre of the World Health Organization, each year 3,000–5,000 children are born with this chromosome disorder, and about 250,000 families have at least one member with Down syndrome in the U.S. Down syndrome is caused by numerical aneuploidy,…
NEW YORK (Reuters Health)—Romosozumab improves bone mineral density (BMD) in men with osteoporosis, but safety concerns are holding up its approval in the U.S. Up to 2 million men in the U.S. have osteoporosis, and up to 13 million have osteopenia, researchers note in a report online June 20 in The Journal of Clinical Endocrinology…
New research suggests circulating hsa-miR-122-5p and hsa-miR-4516 may become diagnostic biomarkers for osteoporosis. The study found the presence of these microRNAs were associated with osteoporotic fragility fractures and reduced bone mineral density…
Rheumatologists often rely on magnetic resonance imaging (MRI) in the evaluation of suspected muscular diseases. Here, we describe a case in which unexpected findings on MRI pointed to a diagnosis rarely considered as a mimicker of rheumatologic disease. The Case A 19-year-old man of Middle Eastern descent was admitted to our hospital for evaluation of…
NEW YORK (Reuters Health)—Romosozumab shows smaller benefits for increasing bone mineral density (BMD) in the second year of treatment compared to the first, new research suggests. The extension of a phase 2 study in postmenopausal women with low bone mass also found BMD decreased sharply when patients on romosozumab were switched to placebo after two…
NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…
NEW YORK (Reuters Health)—Abaloparatide appears to be a safe and effective drug for increasing bone mineral density (BMD) in women 80 and older, new research shows. The study is a post hoc analysis of the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, which found patients who received abaloparatide subcutaneously for 18 months had increased…
NEW YORK (Reuters Health)—After discontinuation of teriparatide, increases in bone mineral density (BMD) are greater with denosumab than with zoledronic acid, but whether that translates into a decreased fragility fracture risk remains unknown, researchers say. Teriparatide was the first anabolic treatment approved for osteoporosis in the U.S. It has been shown to increase BMD, and…